Breaking News Dispatch: A Non-Invasive Alzheimer's Treatment, Early Detection, and More

Sinaptica Therapeutics presented clinical trial results showing their personalized, non-invasive brain stimulation treatment slowed cognitive decline in people with mild-to-moderate Alzheimer's. The company's scientific co-founder Giacomo Koch, MD, received funding from Alzheimer's Disease Research to enable human studies.

"We are pleased to support this important Phase 2, 1-year clinical study," said Diane Bovenkamp, PhD, Vice President of Scientific Affairs at BrightFocus Foundation. "We pride ourselves on supporting bold, innovative approaches, and are thrilled to see such a successful outcome from a noninvasive therapy, providing a new avenue of hope for patients with this new class of electromagnetic therapeutics."

Participants underwent a type of brain stimulation called repetitive transcranial magnetic stimulation, which targeted an important brain network for memory over a period of 52 weeks. People with Alzheimer's who received the treatment showed little change in their cognition after one year, suggesting slowing of the disease.

"We're excited that our non-invasive precision neuromodulation therapy continues to demonstrate promise in slowing Alzheimer's," said Dr. Koch in a statement. "These latest results provide new additional evidence at 12 months, building on our prior positive six-month Phase 2 study, supporting the potential for [this treatment] to slow the impairment of cognitive functions, preserve activities of daily living, and reduce behavioral disturbances in Alzheimer's patients, with no significant side-effects." The study was featured on NBC News.

Learn more about approved treatments for Alzheimer's disease.